226 related articles for article (PubMed ID: 34518988)
1. Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma.
Serrano D; Podger L; Barnes G; Song J; Tang B
Qual Life Res; 2022 Mar; 31(3):937-950. PubMed ID: 34518988
[TBL] [Abstract][Full Text] [Related]
2. International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18.
Chie WC; Blazeby JM; Hsiao CF; Chiu HC; Poon RT; Mikoshiba N; Al-Kadhimi G; Heaton N; Calara J; Collins P; Caddick K; Costantini A; Vilgrain V; Trinquart L; Chiang C;
Hepatology; 2012 Apr; 55(4):1122-9. PubMed ID: 22105642
[TBL] [Abstract][Full Text] [Related]
3. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18).
Mikoshiba N; Tateishi R; Tanaka M; Sakai T; Blazeby JM; Kokudo N; Koike K; Kazuma K
Health Qual Life Outcomes; 2012 May; 10():58. PubMed ID: 22651810
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
6. Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients.
Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AK; Tang NL; Chu CM; Hui J; Lee KF; Yu S; Yeo W
Qual Life Res; 2019 Sep; 28(9):2597-2607. PubMed ID: 31037590
[TBL] [Abstract][Full Text] [Related]
7. The association of liver function and quality of life of patients with liver cancer.
Li L; Mo F; Hui EP; Chan SL; Koh J; Tang NLS; Yu SCH; Yeo W
BMC Gastroenterol; 2019 May; 19(1):66. PubMed ID: 31046687
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of the Simplified Chinese Version of EORTC QLQ-HCC18 for Patients with Hepatocellular Carcinoma.
Yang Z; Wan C; Li W; Cun Y; Meng Q; Ding Y; Chen P
Cancer Invest; 2015; 33(8):340-6. PubMed ID: 26046473
[TBL] [Abstract][Full Text] [Related]
9. Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma.
Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AKC; Tang NLS; Lee KF; Lai PBS; Yu SCH; Yeo W
Cancer Manag Res; 2019; 11():2719-2727. PubMed ID: 31040713
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
11. Psychometric properties of the Urdu version of the EORTC QLQ-H&N35 (European organization for research and treatment of cancer head and neck module) quality of life tool.
Zahid N; Martins RS; Zahid W; Azam I; Ikram M; Hassan A; Bhamani SS; Jabbar AA; Asad N; Akhtar S; Siddiqui MI; Awan MS; Ahmad K
BMC Psychol; 2022 Aug; 10(1):194. PubMed ID: 35934706
[TBL] [Abstract][Full Text] [Related]
12. International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26.
Sztankay M; Aaronson NK; Arraras JI; Basso U; Bumbasirevic U; Efficace F; Giesinger JM; Johnson CD; van Leeuwen M; Oberguggenberger AS; Sosnowski R; Young T; Holzner B;
BMC Cancer; 2018 Nov; 18(1):1104. PubMed ID: 30419889
[TBL] [Abstract][Full Text] [Related]
13. International Psychometric Validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12).
Weis J; Tomaszewski KA; Hammerlid E; Ignacio Arraras J; Conroy T; Lanceley A; Schmidt H; Wirtz M; Singer S; Pinto M; Alm El-Din M; Compter I; Holzner B; Hofmeister D; Chie WC; Czeladzki M; Harle A; Jones L; Ritter S; Flechtner HH; Bottomley A;
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28376231
[TBL] [Abstract][Full Text] [Related]
14. International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).
Oerlemans S; Efficace F; Kyriakou C; Freitas AC; Shamieh O; Creutzberg CL; Lehmann J; Petranovic D; Nagele E; Bredart A; Dong D; Scholz CW; Caocci G; Molica S; Griskevicius L; Xochelli A; Kieffer JM; Agelink van Rentergem JA; Alrjoub W; Mueller A; Gomes Da Silva M; Alves da Costa F; Malak S; Cocks K; van de Poll-Franse LV;
Cancer; 2023 Sep; 129(17):2727-2740. PubMed ID: 37204189
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
16. Reliability and validity of the Amharic version of European Organization for Research and Treatment of cervical Cancer module for the assessment of health related quality of life in women with cervical cancer in Addis Ababa, Ethiopia.
Araya LT; Gebretekle GB; Gebremariam GT; Fenta TG
Health Qual Life Outcomes; 2019 Jan; 17(1):13. PubMed ID: 30642359
[TBL] [Abstract][Full Text] [Related]
17. Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer.
Ripping TM; Rammant E; Witjes JA; Aaronson NK; van Hemelrijck M; van Hoogstraten LMC; ; Kiemeney LA; Aben KKH
Health Qual Life Outcomes; 2022 Dec; 20(1):171. PubMed ID: 36581934
[TBL] [Abstract][Full Text] [Related]
18. Cultural adaptation and validation of the Korean version of the EORTC QLQ-CR29 in patients with colorectal cancer.
Ihn MH; Lee SM; Son IT; Park JT; Oh HK; Kim DW; Kang SB
Support Care Cancer; 2015 Dec; 23(12):3493-501. PubMed ID: 25824366
[TBL] [Abstract][Full Text] [Related]
19. International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15.
Hjermstad MJ; Bergenmar M; Bjordal K; Fisher SE; Hofmeister D; Montel S; Nicolatou-Galitis O; Pinto M; Raber-Durlacher J; Singer S; Tomaszewska IM; Tomaszewski KA; Verdonck-de Leeuw I; Yarom N; Winstanley JB; Herlofson BB;
Support Care Cancer; 2016 Sep; 24(9):3915-24. PubMed ID: 27113466
[TBL] [Abstract][Full Text] [Related]
20. Psychometric properties of the EORTC QLQ-C30 in Uganda.
Naamala A; Eriksson LE; Orem J; Nalwadda GK; Kabir ZN; Wettergren L
Health Qual Life Outcomes; 2021 Apr; 19(1):131. PubMed ID: 33892718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
